U.S. stocks edge higher; solid earnings season continues
On Wednesday, Mizuho (NYSE:MFG) Securities reaffirmed its positive stance on Evolus (NASDAQ:EOLS), a $632 million market cap healthcare company, with a continued Outperform rating and a steady price target of $25.00. According to InvestingPro data, analyst targets for the stock range from $20 to $27, with the company showing strong revenue growth of 25% in the last twelve months. The endorsement came despite the recent announcement of CFO Sandra Beaver’s transition to a new role as CFO of Lyra Health, a private company specializing in AI-powered mental health and wellness solutions.
Evolus’ leadership, including CEO David Moatazedi, remains confident in the company’s direction and its ability to achieve its projected sales and non-GAAP profitability by 2025, as well as its sales outlook for 2028. The reassurance from Mizuho’s analysis follows direct communications with the Evolus management team. This confidence is supported by the company’s strong liquidity position, with InvestingPro analysis showing a healthy current ratio of 2.34 and a "GOOD" overall financial health score.
Sandra Beaver’s decision to join Lyra Health, which attained unicorn status in 2020, is seen as a strategic career move rather than a reflection of any diminished confidence in Evolus. She has previously collaborated with Lyra’s CEO at Experian (OTC:EXPGF) and is not planning to sell her approximately 167,000 shares in Evolus, signaling her belief in the company’s long-term prospects.
Despite the executive change, Mizuho’s analysis suggests that investors should not be concerned and advises purchasing Evolus stock if any market fluctuations present a buying opportunity. The firm’s recommendation is based on the strength of the company’s business fundamentals and the anticipated trajectory of growth and profitability.
The continuity of Evolus’ business strategy and the optimistic outlook shared by its departing CFO underscore the company’s stability and potential for future success. Mizuho’s reiteration of the Outperform rating and the $25.00 price target reflects confidence in Evolus’ market position and growth prospects. InvestingPro analysis indicates the stock is currently slightly undervalued, with additional insights available in the comprehensive Pro Research Report, which provides deep-dive analysis of this and 1,400+ other US stocks.
In other recent news, Evolus, Inc. reported its first-quarter 2025 earnings, which revealed a larger-than-expected loss. The company posted an earnings per share (EPS) of -$0.30, missing analysts’ forecasts of -$0.09. Despite this, Evolus saw a 15.5% year-over-year revenue increase to $68.5 million, although this was below the anticipated $72.51 million. Evolus has reaffirmed its full-year revenue guidance, projecting between $345 million and $355 million, with expectations for significant growth driven by new product launches like Evolisse. In another development, Evolus’ Evolysse HA gels have demonstrated superior performance compared to Restylane in a clinical study, which could bolster the company’s market position. Meanwhile, Chief Financial Officer Sandra Beaver announced her resignation to join a private mental health and wellness technology firm. The company is actively searching for her successor while assuring stakeholders of a smooth transition. These recent developments underscore Evolus’ ongoing efforts to expand its product portfolio and maintain its financial health amidst market challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.